Olympus, Shimadzu And Keio University To Establish ¥2 Billion Cancer Research Facility
This article was originally published in PharmAsia News
Japanese medical device makers Olympus and Shimadzu and Keio University will collaborate in establishing a cancer treatment research and development center in 2010. The center will be the first in Japan to focus on developing less invasive therapies and next generation medical devices and drugs such as ultra-compact robots. Out of the ¥2 billion investment, the Japanese government plans to provide ¥800 million. Two major industrial companies Yokogawa Electric and Hamamatsu Photonics also plan to join in the project. Keio estimates ¥25 billion in economic profit as a result of the new research center. (Click here for more - Japanese language
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.